UNSPSC 51421607: Diflorasone diacetate

This classification denotes a therapeutic glucocorticoid with the molecular formula C26H32F2O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7W2J09SCWX, chemically known as pregna-1,4-diene-3,20-dione, 17,21-bis(acetyloxy)-6,9-difluoro-11-hydroxy-16-methyl-, (6.alpha.,11.beta.,16.beta.)- but more generally known as diflorasone diacetate, which bears US NIH Compound Identifier 3056. European Medicines Agency schedules Diflorasone diacetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01693MIG.

UNSPSC 51421607 Diflorasone diacetate is a Commodity code that in recent state and local procurement shows little relevant activity aligned with its nominal scope. A single recent opportunity tagged to this code—Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026—solicits Naloxone and Safe Drug Deactivation Systems rather than the corticosteroid pharmaceutical named in the code. The mismatch suggests either a tagging error in the state or local procurement system or a scope drift that does not reflect the code's primary purpose. The Seminole County procurement itself targets emergency response and community health initiatives, with annual volumes of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems delivered quarterly to the Seminole County Community Health Building in Sanford, Florida.

The Seminole County opportunity, due July 26, 2023 (a response deadline now substantially past as of October 2026), required bidders to submit electronic bids through the county's e-Procurement Portal, include all shipping and delivery costs, hold drug-free workplace and E-Verify certification, and maintain workers' compensation and general liability insurance. The contract carried a two-year initial term with a one-year renewal option and a three-month probationary termination clause. No explicit set-aside designations appear in the notice. With only one recent opportunity visible under this code and that opportunity plainly focused on emergency medical supplies rather than diflorasone diacetate itself, the code shows minimal actionable activity for vendors in the pharmaceutical or dermatological therapeutic space.